HSITF:OTO-Hadasit Bio Holdings Ltd (USD)

COMMON STOCK | Biotechnology | OTC Pink

Last Closing

USD 0.25

Change

0.00 (0.00)%

Market Cap

USD 0.07B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Hadasit Bio Holdings Ltd operates as an investment holding company. The Company through it holdings is engaged in research and development in the medical and biotechnology fields.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

N/A

USD 564.56B
CMXHF CSL Limited

N/A

USD 89.03B
CSLLY CSL Ltd

N/A

USD 84.45B
UCBJF UCB SA

N/A

USD 25.40B
UCBJY UCB SA ADR

N/A

USD 24.49B
ARGNF argenx SE

N/A

USD 22.81B
GNMSF Genmab A/S

N/A

USD 18.12B
WXIBF WuXi Biologics

N/A

USD 7.17B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 7.17B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.76B

ETFs Containing HSITF

EMOM:PA BNP Paribas Easy ESG Equi.. 4.95 % 0.00 %

N/A

USD 2.00M
MOED:PA BNP Paribas Easy - Equity.. 4.95 % 0.00 %

N/A

USD 2.20M
MOED:F BNP Paribas Easy - Equity.. 4.95 % 0.00 %

N/A

USD 2.20M
MOEU:F BNP Paribas Easy - Equity.. 4.95 % 0.00 %

N/A

USD 2.36M
MOED:XETRA BNP Paribas Easy - Equity.. 4.95 % 0.00 %

N/A

USD 2.20M
MOEU:XETRA BNP Paribas Easy ESG Equi.. 4.95 % 0.00 %

N/A

USD 2.20M
XS3R:LSE Xtrackers MSCI Europe Con.. 4.90 % 0.00 %

N/A

USD 0.07B
DXSK:F Xtrackers - Stoxx Europe .. 4.90 % 0.00 %

N/A

USD 0.07B
DXSK:XETRA Xtrackers - Stoxx Europe .. 4.90 % 0.00 %

N/A

USD 0.07B
IAEX:LSE iShares AEX UCITS ETF EUR.. 2.91 % 0.00 %

N/A

USD 0.63B
XFI:CA 1.96 % 0.51 %

N/A

N/A
RODM Hartford Multifactor Deve.. 0.99 % 0.31 %

N/A

USD 1.13B
MVAE:LSE 0.77 % 0.00 %

N/A

N/A
MVEX:LSE 0.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -28.57% 58% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.57% 58% F 36% F
Trailing 5 Years  
Capital Gain -80.77% 46% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.77% 46% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain -12.89% 33% F 19% F
Dividend Return -12.89% 33% F 18% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 75.16% 51% F 38% F
Risk Adjusted Return -17.15% 37% F 26% F
Market Capitalization 0.07B 34% F 27% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector